环保署乳衍生物,5,6-diHETE乳,改善肺动脉高血压在一个单克罗他林诱导的模型
Karthik Dhananjayan1,2, Offir Ertracht3, Shaul Atar3,4,5
1The Laboratory of Vascular Signaling Research, MIGAL-Galilee Research Institute, Ltd., Kiryat Shmona, Israel.
Frontiers in pharmacology
|July 25, 2025
概括
5,6-diHETE乳 (EPA-L) 在肺高血压的小鼠模型中有效降低了肺动脉压和血管重塑. 这种脂肪酸代谢产物通过向血管变化,显示出治疗肺高血压的前景.
科学领域:
- 心血管研究研究心血管研究
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺动脉高血压 (PAH) 是一种严重的疾病,其特征是血管重塑和右心室衰竭.
- 目前的PAH治疗侧重于血管扩张,但需要针对血管改造的疗法.
- 5,6-diHETE乳 (EPA-L),EPA脂肪酸的代谢物,已经显示出血管扩张作用.
研究的目的:
- 评估EPA-L在单克罗他林 (MCT) 诱导的肺动脉高血压的老鼠模型中的疗效.
- 确定EPA-L是否可以减轻与PAH相关的血管改造.
主要方法:
- 鼠被诱导使用MCT (60毫克/公斤) 来建模PAH.
- 受MCT诱导的老鼠接受了盐水或不同剂量的EPA-L (0.3或3.0毫克/公斤) 五天.
- 进行了功能性,血液学和组织学评估.
主要成果:
- 治疗EPA-L显著降低了肺动脉平均压力和肺动脉高峰时间.
- 服用EPA-L降低了动脉动脉亲密介质厚度,这表明血管重塑减少.
- 虽然EPA-L改善了缺氧指数,但它没有显著影响巨细胞透或全身炎症标志物.
结论:
- EPA-L在减轻MCT诱导的肺高血压方面显示出显著的治疗潜力.
- EPA-L改善了血液动力学参数,并减少了PAH中的血管重塑.
- EPA-L是开发针对血管修饰的新型肺高血压治疗药物的有希望的候选者.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
225
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
225
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
254
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
254
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
254
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
259
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
259
01:19Antiasthma Drugs: Leukotriene Modifiers
482
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
482